Archived explainer. For the current picture see today's JNJ page.
JOHNSON & JOHNSON (JNJ) is drawing unusual attention today. Our newswire has captured 7 stories on JNJ across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Johnson & Johnson (JNJ) stock is moving lower today, down 1.4% from its close of $257.43 to $253.78 as of the previous session. The decline comes amid mixed market sentiment ahead of its Q2 earnings report on July 15 and a broader earnings season that has seen heightened volatility across major names. Analyst coverage and recent price action suggest a cautious outlook despite the company’s strong fundamentals and recent revenue growth.
Analysts are divided on Johnson & Johnson’s near-term prospects, with several reports highlighting the company’s upcoming earnings as a key event. According to Seeking Alpha, analysts expect an upbeat Q2 print despite headwinds for its Stelara drug, while TipRanks notes that JNJ shares are up 25% year-to-date. Yahoo Finance emphasizes JNJ’s recent full-year revenue guidance and its position as a dividend king. However, the stock’s recent performance has been under pressure, with the price falling below $258 after opening near all-time highs. Meanwhile, external context from Benzinga highlights market optimism, with some experts projecting a rally to $282 or $300.
Recent insider transactions also add nuance: EVP Kathryn E. Wengel sold $2.4 million worth of shares on June 11. On the retail side, there is no significant social chatter, though congressional trades show multiple buys of $1,001, $15,000 by Democrats Ro Khanna and Lloyd Doggett in recent weeks.
The stock has seen a sharp intraday pullback, with a morning high of $258.50 giving way to a low of $252.14 before settling at $252.78. Volume has been unusually light at 2.5 million shares, just 0.3 times the 3-month average. The AI sentiment across seven stories is 58, slightly above neutral, but the 52-week tape has seen 85 fresh lows on July 14, indicating broader market weakness. Unusual options activity has also skewed heavily to calls, with a notable $2.7 million print reported in the last 36 hours.
Johnson & Johnson’s Q2 earnings report on July 15 will be the key event to monitor. Analysts are watching for updates on Stelara performance, segment sales, and full-year guidance. The stock’s ability to hold above $253.78 and respond to earnings will determine its near-term direction. Coverage breadth and sentiment shifts in the coming days will also be telling.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Preview J&J (JNJ) Q2 earnings July 15: EPS/revenue estimates, segment sales outlook, Stelara risk, and guidance updates—get the key takeaways now.
Johnson and Johnson just raised its full-year outlook toward a historic $100 billion revenue target, yet the stock still trades well below where our model says it should be. The real question is whether the pipeline can outrun the headwinds closing in fast.
Healthcare products group Johnson Johnson ($JNJ) reports Q2 earnings this week – July 15. Its shares are up 25% in the year-to-date, helped by demand for its ...
Johnson & Johnson (NYSE:JNJ) and Coca-Cola (NYSE:KO) both delivered Q1 2026 beats and both are being crowded into by capital rotating out of tech. JNJ has broken out past $259, while KO just tagged an all-time high near $84.14. That backdrop makes this a real premium-defensive showdown. Pharma Pipeline Muscle Meets Beverage Brand Muscle JNJ ... JNJ Vs. KO: Which Dividend Stock Is The Better Buy?
Johnson & Johnson (NYSE:JNJ) is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the setup leaves little to debate. The stock has already told you what it thinks of the fundamentals, rising nearly 25% year to date and nearly 66% over the past year. Yet the ... The Real Case for Buying Johnson & Johnson (JNJ) Before July 15
Johnson Johnson ($JNJ) is scheduled to report its fiscal second-quarter results before the market opens on July 15. JNJ stock is a “Dividend King” because it ...
This week, several major companies will be reporting earnings. Among them are Netflix (NFLX), Bank of America (BAC), Johnson & Johnson (JNJ), GE Aerospace (GE), JPM...
More on JNJ: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier JNJ move explainers: 2026-07-22 · 2026-07-21 · 2026-07-14